GlassScriptPhysician profile
Brianne O En
NPI 1477274942
$2,092.46
in general payments reported to CMS, 2019-2025
16 companies · $869 in 2025
The $869 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $303 · 2024: $921 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.97 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.99 | 2023-2025 | |
| Axsome Therapeutics, INC. | $338.87 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $324.89 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.02 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $164.60 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $150.77 | 2023-2025 | Spravato, Invega |
| Pfizer INC. | $117.79 | 2024 | |
| Alkermes, INC. | $99.59 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $92.84 | 2023-2025 | Fanapt, Hetlioz |
| Indivior INC. | $72.14 | 2023-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $34.29 | 2023-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $28.06 | 2025 | Rexulti |
| Orexo US, INC. | $17.14 | 2024 | Zubsolv |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.19 | 2025 | Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $14.56 | 2025 | Cobenfy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $13.72 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne En listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.